Time of Disease‐Modifying Antirheumatic Drug Start in Juvenile Idiopathic Arthritis and the Likelihood of a Drug‐Free Remission in Young Adulthood

Objective To study juvenile idiopathic arthritis (JIA) long‐term outcomes in relation to the time of initiation of biologic disease‐modifying antirheumatic drug (bDMARD). Methods Outcomes of JIA patients prospectively followed by the Biologika in der Kinderrheumatologie (BiKeR) and Juvenile Arthriti...

Ausführliche Beschreibung